Experimental combo targets Hard-to-Treat esophageal cancer
NCT ID NCT04460937
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, so results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Utah Sugarhouse Health Center
Salt Lake City, Utah, 84106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a flexible dosing schedule improve esophageal cancer treatment?
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Experimental drug combo targets Hard-to-Treat GI cancers
- Home monitoring may keep cancer patients out of the ER
- Supercharged immune cells take on stubborn esophageal cancer
- New drug cocktail shows promise for tough stomach cancers